GB Sciences, Inc. (GBLX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 103.44 Thousand USD | -70.64% |
| 2022 | 352.32 Thousand USD | -86.18% |
| 2021 | 2.54 Million USD | -76.4% |
| 2020 | 10.8 Million USD | -24.71% |
| 2019 | 14.35 Million USD | -52.19% |
| 2018 | 30.02 Million USD | 24.84% |
| 2017 | 24.04 Million USD | 84.9% |
| 2016 | 13 Million USD | 434.03% |
| 2015 | 2.43 Million USD | 67.8% |
| 2014 | 1.45 Million USD | 169.8% |
| 2013 | 537.98 Thousand USD | 8029.1% |
| 2012 | 6618.00 USD | -84.85% |
| 2011 | 43.67 Thousand USD | -58.23% |
| 2010 | 104.56 Thousand USD | -60.79% |
| 2009 | 266.72 Thousand USD | 5566.45% |
| 2008 | 4707.00 USD | 514.49% |
| 2007 | 766.00 USD | -99.8% |
| 2006 | 378.7 Thousand USD | 169.81% |
| 2005 | 140.35 Thousand USD | 155.41% |
| 2004 | 54.95 Thousand USD | 407.1% |
| 2003 | 10.83 Thousand USD | -34.47% |
| 2002 | 16.53 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 Q4 | 103.44 Thousand USD | -29.69% |
| 2023 FY | 103.44 Thousand USD | -70.64% |
| 2023 Q2 | 234.18 Thousand USD | 2.17% |
| 2023 Q3 | 147.11 Thousand USD | -37.18% |
| 2023 Q1 | 229.2 Thousand USD | -34.95% |
| 2022 Q3 | 2.79 Million USD | -10.44% |
| 2022 Q1 | 2.34 Million USD | -8.21% |
| 2022 Q4 | 352.32 Thousand USD | -87.38% |
| 2022 Q2 | 3.11 Million USD | 33.19% |
| 2022 FY | 352.32 Thousand USD | -86.18% |
| 2021 Q1 | 10.33 Million USD | -4.4% |
| 2021 FY | 2.54 Million USD | -76.4% |
| 2021 Q4 | 2.54 Million USD | -62.36% |
| 2021 Q2 | 9.93 Million USD | -3.86% |
| 2021 Q3 | 6.77 Million USD | -31.78% |
| 2020 Q2 | 14.25 Million USD | -0.83% |
| 2020 Q4 | 10.8 Million USD | 5.44% |
| 2020 FY | 10.8 Million USD | -24.71% |
| 2020 Q1 | 14.37 Million USD | 0.14% |
| 2020 Q3 | 10.24 Million USD | -28.1% |
| 2019 Q2 | 29.84 Million USD | -2.06% |
| 2019 Q1 | 30.46 Million USD | 1.48% |
| 2019 Q3 | 20.9 Million USD | -29.95% |
| 2019 Q4 | 14.35 Million USD | -31.34% |
| 2019 FY | 14.35 Million USD | -52.19% |
| 2018 Q2 | 30.4 Million USD | 7.59% |
| 2018 FY | 30.02 Million USD | 24.84% |
| 2018 Q4 | 30.02 Million USD | -2.0% |
| 2018 Q3 | 30.63 Million USD | 0.75% |
| 2018 Q1 | 28.26 Million USD | 17.51% |
| 2017 Q2 | 15.15 Million USD | 27.88% |
| 2017 Q1 | 11.85 Million USD | -8.86% |
| 2017 FY | 24.04 Million USD | 84.9% |
| 2017 Q4 | 24.04 Million USD | 46.67% |
| 2017 Q3 | 16.39 Million USD | 8.16% |
| 2016 Q2 | 9.32 Million USD | 161.88% |
| 2016 FY | 13 Million USD | 434.03% |
| 2016 Q1 | 3.55 Million USD | 46.16% |
| 2016 Q4 | 13 Million USD | 42.57% |
| 2016 Q3 | 9.12 Million USD | -2.14% |
| 2015 Q1 | 1.96 Million USD | 35.05% |
| 2015 Q4 | 2.43 Million USD | 4.24% |
| 2015 Q2 | 2.28 Million USD | 16.53% |
| 2015 Q3 | 2.33 Million USD | 2.29% |
| 2015 FY | 2.43 Million USD | 67.8% |
| 2014 Q1 | 3.31 Million USD | 515.58% |
| 2014 FY | 1.45 Million USD | 169.8% |
| 2014 Q4 | 1.45 Million USD | -8.46% |
| 2014 Q3 | 1.58 Million USD | -21.24% |
| 2014 Q2 | 2.01 Million USD | -39.21% |
| 2013 Q1 | 24.53 Thousand USD | 270.69% |
| 2013 Q3 | 3084.00 USD | -33.98% |
| 2013 Q2 | 4671.00 USD | -80.96% |
| 2013 Q4 | 537.98 Thousand USD | 17344.36% |
| 2013 FY | 537.98 Thousand USD | 8029.1% |
| 2012 Q3 | 41.55 Thousand USD | -0.18% |
| 2012 Q1 | 39.59 Thousand USD | -9.35% |
| 2012 Q2 | 41.62 Thousand USD | 5.13% |
| 2012 Q4 | 6618.00 USD | -84.07% |
| 2012 FY | 6618.00 USD | -84.85% |
| 2011 Q4 | 43.67 Thousand USD | -11.33% |
| 2011 Q2 | 62.5 Thousand USD | 11.37% |
| 2011 Q3 | 49.25 Thousand USD | -21.19% |
| 2011 FY | 43.67 Thousand USD | -58.23% |
| 2011 Q1 | 56.12 Thousand USD | -46.33% |
| 2010 FY | 104.56 Thousand USD | -60.79% |
| 2010 Q4 | 104.56 Thousand USD | 49.47% |
| 2010 Q1 | 180.39 Thousand USD | -32.37% |
| 2010 Q2 | 178.88 Thousand USD | -0.83% |
| 2010 Q3 | 69.95 Thousand USD | -60.89% |
| 2009 Q4 | 266.72 Thousand USD | 33.96% |
| 2009 FY | 266.72 Thousand USD | 5566.45% |
| 2009 Q3 | 199.1 Thousand USD | 96.09% |
| 2009 Q2 | 101.53 Thousand USD | 8767.6% |
| 2009 Q1 | 1145.00 USD | -75.67% |
| 2008 Q3 | 456.00 USD | -53.37% |
| 2008 Q4 | 4707.00 USD | 932.24% |
| 2008 Q1 | 1181.00 USD | 54.18% |
| 2008 Q2 | 978.00 USD | -17.19% |
| 2008 FY | 4707.00 USD | 514.49% |
| 2007 FY | 766.00 USD | -99.8% |
| 2007 Q4 | 766.00 USD | -99.79% |
| 2007 Q3 | 357.72 Thousand USD | -17.55% |
| 2007 Q2 | 433.86 Thousand USD | 33.8% |
| 2007 Q1 | 324.27 Thousand USD | -14.37% |
| 2006 Q2 | 413.41 Thousand USD | 48.62% |
| 2006 Q3 | 481.33 Thousand USD | 16.43% |
| 2006 FY | 378.7 Thousand USD | 169.81% |
| 2006 Q4 | 378.7 Thousand USD | -21.32% |
| 2006 Q1 | 278.16 Thousand USD | 98.18% |
| 2005 Q4 | 140.35 Thousand USD | 41.11% |
| 2005 Q3 | 99.46 Thousand USD | 23.75% |
| 2005 FY | 140.35 Thousand USD | 155.41% |
| 2005 Q2 | 80.37 Thousand USD | 18.88% |
| 2005 Q1 | 67.61 Thousand USD | 23.04% |
| 2004 Q1 | 27.94 Thousand USD | 157.9% |
| 2004 Q4 | 54.95 Thousand USD | 16.2% |
| 2004 FY | 54.95 Thousand USD | 407.1% |
| 2004 Q2 | 91.94 Thousand USD | 228.97% |
| 2004 Q3 | 47.29 Thousand USD | -48.56% |
| 2003 Q3 | 6014.00 USD | -3.08% |
| 2003 Q1 | 12.32 Thousand USD | -25.48% |
| 2003 Q2 | 6205.00 USD | -49.65% |
| 2003 Q4 | 10.83 Thousand USD | 80.2% |
| 2003 FY | 10.83 Thousand USD | -34.47% |
| 2002 Q2 | 6766.00 USD | -78.11% |
| 2002 Q4 | 16.53 Thousand USD | -69.34% |
| 2002 Q1 | 30.9 Thousand USD | 0.0% |
| 2002 FY | 16.53 Thousand USD | 0.0% |
| 2002 Q3 | 53.93 Thousand USD | 697.19% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -4378.009% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 94.717% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 99.02% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 81.265% |
| Rebus Holdings, Inc. | 5000.00 USD | -1968.84% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.921% |
| Qrons Inc. | 420.00 USD | -24529.048% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 86.577% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.63% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 78.475% |
| Skye Bioscience, Inc. | 11.94 Million USD | 99.134% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.734% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 98.567% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -35.477% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.903% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 92.777% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -42.945% |
| Mesoblast Limited | 667.9 Million USD | 99.985% |
| Marizyme, Inc. | 22.01 Million USD | 99.53% |
| Genus plc | 1.02 Billion USD | 99.99% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 92.385% |
| Pharming Group N.V. | 462.85 Million USD | 99.978% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 96.878% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 79.272% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 83.502% |
| ContraFect Corporation | 20.67 Million USD | 99.5% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 73.501% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 72.933% |
| IMV Inc. | 31.33 Million USD | 99.67% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 97.505% |
| MultiCell Technologies, Inc. | 126.22 USD | -81853.732% |
| ONE Bio Corp. | 70.08 Million USD | 99.852% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 88.992% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.92% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 76.039% |
| Q BioMed Inc. | 3.51 Million USD | 97.058% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.706% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | 60.409% |
| Biomind Labs Inc. | 73.81 Thousand USD | -40.129% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.977% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 92.86% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.655% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 96.233% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 84.954% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 96.026% |
| Alpha Cognition Inc. | 2.45 Million USD | 95.782% |
| HST Global, Inc. | 1526.00 USD | -6678.637% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 89.53% |
| Halberd Corporation | 10.13 Thousand USD | -921.044% |
| Enzolytics Inc. | 361.7 Million USD | 99.971% |
| Agentix Corp. | 261.39 Thousand USD | 60.426% |
| Resverlogix Corp. | 8.11 Million USD | 98.725% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 94.492% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.998% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.783% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 83.828% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -354.071% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 98.844% |
| AVAX Technologies, Inc. | 7.37 Million USD | 98.598% |
| Zenith Capital Corp. | 7410.00 USD | -1295.978% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.997% |
| Ember Therapeutics, Inc. | 184.00 USD | -56118.478% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 67.856% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | 60.422% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 88.853% |
| Kadimastem Ltd | 2.3 Million USD | 95.51% |
| Helix BioMedix, Inc. | 3.02 Million USD | 96.581% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.804% |
| BioStem Technologies, Inc. | 14.56 Million USD | 99.29% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -81.178% |
| LadRx Corporation | 2.3 Million USD | 95.518% |
| Cell Source, Inc. | 195.17 Thousand USD | 46.999% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 70.747% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 70.747% |
| NovAccess Global Inc. | 62.24 Thousand USD | -66.177% |
| Affymax, Inc. | 7.44 Million USD | 98.61% |
| Itoco Inc. | 1.4 Million USD | 92.612% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -8.138% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | 2.413% |
| Mobile Lads Corp. | 52.00 USD | -198826.923% |
| CytoDyn Inc. | 11.13 Million USD | 99.071% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | 27.649% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -478.535% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 73.165% |
| SYBLEU INC | 330.46 Thousand USD | 68.698% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 74.735% |
| International Stem Cell Corporation | 5.39 Million USD | 98.081% |
| Bioxytran, Inc. | 137.63 Thousand USD | 24.845% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 99.31% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 99.376% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -30.939% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 88.037% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 98.624% |
| Neutra Corp. | 2851.00 USD | -3528.271% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.681% |
| PureTech Health plc | 693.97 Million USD | 99.985% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 98.718% |
| IXICO plc | 15.84 Million USD | 99.347% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 98.751% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.9% |
| CSL Limited | 38.02 Billion USD | 100.0% |
| Cellectis S.A. | 333.99 Million USD | 99.969% |